Lazertinib Outperforms Gefitinib in EGFR-Mutated NSCLC

The third-generation EGFR TKI lazertinib displayed a significant efficacy improvement compared with gefitinib in patients with EGFR-mutated advanced non–small cell lung cancer when given in the first-line.

Related Keywords

,World Health Organization ,Lazertinib Compared With Gefitinib ,Patients With Egfr Mutated Advanced Non Small Cell Lung Cancer ,Laser301 Study ,Nct04248829 ,